WOWp Zomedica Corp

Zomedica to Present at RHK Capital 2019 Disruptive Growth Conference, Fall Investor Summit, and Sidoti & Company Fall 2019 Investor Conference

Zomedica to Present at RHK Capital 2019 Disruptive Growth Conference, Fall Investor Summit, and Sidoti & Company Fall 2019 Investor Conference

ANN ARBOR, Mich., Sept. 03, 2019 (GLOBE NEWSWIRE) -- (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it will present at the RHK Capital 2019 Disruptive Growth Conference on September 4, as well as the Fall Investor Summit on September 16 and the Sidoti & Company Fall 2019 Investor Conference on September 25.

Chief Financial Officer Shameze Rampertab, CPA, CA, will provide an overview of Zomedica’s business during his presentations at the conferences and will be available to participate in one-on-one meetings with registered investors.

RHK Capital 2019 Disruptive Growth Conference

Date: Wednesday, September 4

Time: 4:20 p.m. EDT

Location: Reed Smith, New York, NY

Fall Investor Summit

Date: Monday, September 16

Time: 2:00 p.m. EDT

Location: The Essex House, New York, NY  

Sidoti & Company Fall 2019 Investor Conference

Date: Wednesday, September 25

Time: 3:20 p.m. EDT

Location: Grand Hyatt NYC, New York, NY  

Investors and other interested parties will be able to access live webcasts of the presentations by visiting Zomedica’s website at . A replay of the audio webcasts and presentations will be accessible on the Zomedica website following the events.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline, and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit .

Follow Zomedica

  • Email Alerts:
  • LinkedIn:
  • Facebook:
  • Twitter:

Reader Advisory

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Investor Relations Contact

Shameze Rampertab, CPA, CA



+1 647.283.3630

PCG Advisory Group

Kirin Smith, COO



+1 646.863.6519

Media Contact

Christy Penka



+1 734.369.2555

EN
03/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zomedica Corp

 PRESS RELEASE

Zomedica Appoints Larry Heaton as President and Announces CEO Successi...

Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan ANN ARBOR, Mich., Oct. 04, 2021 (GLOBE NEWSWIRE) --  (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that Larry Heaton has been appointed President effective October 1, 2021. Mr. Heaton will assume the role of Chief Executive Officer upon the retirement of current Chief Executive Officer Robert Cohen on October 31, 2021. Following his retirement, Mr. Cohen will remain on the Board of ...

 PRESS RELEASE

Zomedica Acquires PulseVet

Zomedica Acquires PulseVet ANN ARBOR, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that it had acquired the Pulse Veterinary Technologies businesses for $70.9 million in an all-cash, stock transaction. Pulse Veterinary Technologies (“PulseVet”) is a world leader in electro-hydraulic shock wave technology for the treatment of a wide variety of conditions in veterinary patients. The high-energy sound w...

 PRESS RELEASE

Sean Whelan Appointed to Board of Directors

Sean Whelan Appointed to Board of Directors ANN ARBOR, Mich., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that Sean Whelan has been appointed to its Board of Directors to fill the vacancy created by the resignation of Christopher Wolfenberg. Robert Cohen, Zomedica’s Chief Executive Officer, commented that: “We all are very pleased to be joined by an executive with Sean’s sterling background. His broad and deep experience and expert...

 PRESS RELEASE

Zomedica Announces Second Quarter 2021 Financial Results

Zomedica Announces Second Quarter 2021 Financial Results TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales ANN ARBOR, Mich., Aug. 11, 2021 (GLOBE NEWSWIRE) --  (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three and six months ended June 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of Americ...

 PRESS RELEASE

Zomedica Announces 2021 Annual Meeting Results

Zomedica Announces 2021 Annual Meeting Results ANN ARBOR, Mich., July 30, 2021 (GLOBE NEWSWIRE) --  (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2021 Annual Virtual-Only Meeting of Shareholders (the “Meeting”) held on July 30, 2021. At the Meeting, the Company’s shareholders approved the items of business as follows: Election of Jeffrey Rowe, Robert Cohen, Johnny D. Powers, Rodney Williams, Chris MacLeod and Christopher Wolfenberg as directors; ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch